Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Leuprolide acetate

Ogawa, Y., Yamamoto, M., Takada, S., Okada, H., and Shimamoto, T., Controlled-release of leuprolide acetate from... [Pg.40]

Eating disorders leuprolide acetate, nafarelin, gosarelin)... [Pg.854]

The systemic delivery of drugs was pioneered with a pMDI product, leuprolide acetate, for the treatment of prostate cancer. A considerable amount of work was conducted to demonstrate feasibility of delivery of this... [Pg.499]

There are no comparative trials of LHRH agonists, so the choice is usually based on cost (Table 65-1) and on patient and physician preference. Leuprolide acetate is administered daily. Leuprolide depot and goserelin acetate implant can be administered monthly, or every 12 or 16 weeks. [Pg.729]

Leucoquinizarin, 9 328-329 Leucoxenes, 25 31, 33 Leukocytes, 4 83, 89 Leuprolide acetate formulations, encapsulated, 76 453 Leurocristine (vincristine), 2 77, 98, 99 Leuseramycin, 20 136 Leutinizing hormone releasing hormone analogue, registered for use in aquaculture in Australia, 3 222t Levans, 23 481 in beets, 23 463... [Pg.518]

Adjei A, Sundberg D, Miller J, Chun A (1992) Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm Res 9 244-249. [Pg.155]

Hu leuprolide acetate (human) 1209 Da Aerosol (MDI) Solution/ suspension 4-18% independent of formulation... [Pg.62]

Dog leuprolide acetate (dog) 1209 Da IT instillation Solution 4.6-95% increasing with deposition distance from epiglottis... [Pg.62]

Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copolyflactic glycohc) acid. Chem Pharm Bull 1988 36 1095-1103. [Pg.202]

Gonadotropin-releasing hormone (GnRH) analogs buserelin acetate goserelin acetate leuprolide acetate nafarelin acetate... [Pg.606]

Figure 8 (A) In vitro permeability of candidate drug molecules in the presence of synergistic combinations of penetration enhancers (SCOPE) formulations. Open circles indicate passive skin permeability and closed circles indicate skin permeability in the presence of SCOPE formulations as a function of the molecular weight of the solute. (B) In vivo delivery of leuprolide acetate, a synthetic analogue of LHRH in hairless rat model, y-axis shows blood plasma concentration of leuprolide acetate as a function of time for control formulation (open circles) and SCOPE formulation (closed circles). Abbreviation-. LHRH, luteinizing hormone-releasing hormone. Figure 8 (A) In vitro permeability of candidate drug molecules in the presence of synergistic combinations of penetration enhancers (SCOPE) formulations. Open circles indicate passive skin permeability and closed circles indicate skin permeability in the presence of SCOPE formulations as a function of the molecular weight of the solute. (B) In vivo delivery of leuprolide acetate, a synthetic analogue of LHRH in hairless rat model, y-axis shows blood plasma concentration of leuprolide acetate as a function of time for control formulation (open circles) and SCOPE formulation (closed circles). Abbreviation-. LHRH, luteinizing hormone-releasing hormone.
Viadur Leuprolide acetate DMSO SC, sustained release... [Pg.278]

Lupron Depot PLA Leuprolide acetate Prostate cancer, endometreosis... [Pg.349]

In a phase II study of androgen suppression therapy for prostate cancer, 95 patients with recurrent or metastatic prostate cancer received cyclical 8-month periods of treatment with leuprolide acetate and nilutamide, with... [Pg.155]

In a randomized, placebo-controlled study in women who received leuprolide acetate depot 11.25 mg intramuscularly with tibolone 2.5 mg/day (n = 36), leuprolide acetate depot 11.25 mg with placebo (n = 37), or a placebo injection with placebo tablets (n = 39), irritable bowel syndrome related to the menstrual cycle improved in those who received leuprolide (5). There were hot flushes in those who took leuprolide compared with placebo no data were given about the frequency of hot flushes, but there were no withdrawals because of this symptom. Amenorrhea also occurred. Both flushing and amenorrhea are expected adverse effects of leuprolide. [Pg.487]

Add-back estrogen replacement reduces the frequency and severity of these symptoms without apparently compromising the effectiveness of gonadorelin in women with endometriosis (19,27). In a randomized, multicenter, double-blind comparison of intranasal nafarelin twice daily and depot leuprolide acetate monthly for 6 months in 192 young women with endometriosis, nafarelin caused fewer hypoestrogenic symptoms, although the... [Pg.488]

A 41-year-old woman developed painless thyroiditis after receiving leuprolide acetate for 4 months. [Pg.488]

Two men developed hyperglycemia after using leuprolide acetate (35). [Pg.488]

A 61-year-old Japanese man with prostate cancer had had well controlled diabetes for 6 years (HbAic less than 6.4%). He received leuprolide acetate subcutaneously 3.75 mg/month and oral flutamide 250 mg/ day. Three weeks after the second injection his fasting glucose was 18 mmol/1 and HbAlc 8.0%. [Pg.488]

See other pages where Leuprolide acetate is mentioned: [Pg.563]    [Pg.563]    [Pg.588]    [Pg.1365]    [Pg.502]    [Pg.715]    [Pg.591]    [Pg.617]    [Pg.592]    [Pg.619]    [Pg.100]    [Pg.63]    [Pg.724]    [Pg.732]    [Pg.682]    [Pg.620]    [Pg.235]    [Pg.236]    [Pg.458]    [Pg.484]    [Pg.516]    [Pg.516]    [Pg.920]    [Pg.278]    [Pg.279]    [Pg.346]    [Pg.347]    [Pg.563]    [Pg.563]    [Pg.358]    [Pg.488]   
See also in sourсe #XX -- [ Pg.682 , Pg.683 ]

See also in sourсe #XX -- [ Pg.178 , Pg.3360 ]

See also in sourсe #XX -- [ Pg.44 , Pg.316 ]

See also in sourсe #XX -- [ Pg.280 ]

See also in sourсe #XX -- [ Pg.344 ]

See also in sourсe #XX -- [ Pg.385 ]

See also in sourсe #XX -- [ Pg.7 , Pg.25 , Pg.54 , Pg.219 ]



SEARCH



Leuprolide

© 2024 chempedia.info